NCT00929682

Brief Summary

In a prospective randomised study involving primiparous women in spontaneous uncomplicated labour with cervical dilatation \> 7 cm, epidural analgesia will be given with an initial volume of 20 mL anaesthetic solution, followed by a standardised algorithm of top-up manual injections to achieve analgesia, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1. The anaesthetic solution will be levobupivacaine presented in 100-mL bags from the market, 0.0625%, or 0.125%, in which 10 mL (50 µg) of sufentanil will be added. The final concentrations will be 0.568 and 1.136 mg.mL-1 respectively, both with sufentanil 0.45 µg.mL-1. Parturients and midwifes assessing pain during labour will be blinded to the design

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
136

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2007

Shorter than P25 for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 26, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 29, 2009

Completed
Last Updated

April 4, 2013

Status Verified

April 1, 2013

Enrollment Period

9 months

First QC Date

June 26, 2009

Last Update Submit

April 2, 2013

Conditions

Keywords

LaborEpidural analgesiaLocal anestheticsLevobupivacaineOpiatesPatient-controlledActive spontaneous labor requiring epidural analgesia

Outcome Measures

Primary Outcomes (1)

  • - Spontaneous pain during labour (on VAS). - Number of required additional epidural boluses, either self-administered or medically given as a rescue.

    during labour

Secondary Outcomes (1)

  • - Pain at delivery - Pain at post-delivery sutures - Motor block - Duration of labour - Obstetrical events (cesarean, instrumental delivery)

    during labour

Study Arms (2)

Levobupivacaine 0.568mg.mL

EXPERIMENTAL
Drug: Randomization between two referenced treatments

Levobupivacaine 1.136mg.mL

OTHER
Drug: Randomization between two referenced treatments

Interventions

Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1. Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.

Levobupivacaine 0.568mg.mLLevobupivacaine 1.136mg.mL

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Parturient \> 18 years old
  • ASA physical status 1 or 2
  • Primiparity
  • Singleton
  • Gestational age \> 36 weeks
  • Spontaneous labour with cervical dilatation \> 7 cm

You may not qualify if:

  • Gestational age \< 36 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Tixier S, Bonnin M, Bolandard F, Vernis L, Lavergne B, Bazin JE, Duale C. Continuous patient-controlled epidural infusion of levobupivacaine plus sufentanil in labouring primiparous women: effects of concentration. Anaesthesia. 2010 Jun;65(6):573-580. doi: 10.1111/j.1365-2044.2010.06369.x.

Related Links

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Martine Bonnin, MB

    University Hospital, Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2009

First Posted

June 29, 2009

Study Start

June 1, 2007

Primary Completion

March 1, 2008

Study Completion

March 1, 2008

Last Updated

April 4, 2013

Record last verified: 2013-04